Lodo Therapeutics was launched by Accelerator Corporation to advance a metagenomics-driven, culture-independent platform that discovers genetically encoded small molecules from uncultured soil bacteria and the human microbiome. The company holds a license from The Rockefeller University to practice and expand Sean Brady’s discovery platform and aims to develop therapeutics across infectious disease, oncology, metabolic disorders and rare diseases. Early programs build on Brady’s prior work in antibiotics and include efforts against tuberculosis and drug-resistant infections. Lodo plans to advance drug candidates toward the initiation of human clinical trials, working in partnership with the Bill & Melinda Gates Foundation. David Pompliano, Ph.D., will serve as interim chief scientific officer alongside co-founder Sean Brady. Lodo’s offices and labs will be based at Accelerator’s facilities in the Alexandria Center for Life Science in New York City.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2016